Clinical trial · Observational
Optimising Molecular Radionuclide Therapy
OPTIMISING MOLECULAR RADIONUCLIDE THERAPY: The Role of Quantitative SPECT/CT & PET/CT and Radiation Dosimetry (SELFIE)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This project will examine the role of the whole body, PET and SPECT imaging before, during and after radionuclide treatment for 177Lu-Dotatate therapy, whole body and SPECT imaging for 131-I for thyroid cancer therapy, and whole-body imaging for 131I for hyperthyroidism therapy. Whole-body and SPECT images will be linked to personal dosimeter readings to determine whether * Current radiation protection advice for patients receiving radionuclide treatment is appropriate. * Radiopharmaceutical retention and/or SUV change in patients undergoing repeated radionuclide treatments. * Data combined from early (quantitative imaging) and late (whole-body dose rate measurements) could support individual treatment planning for patients undergoing repeated cycles of molecular therapy.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hyperthyroidism | — | UNRESOLVED | — |
| Neuroendocrine Tumors | Neuroendocrine Tumor | ONTOLOGY_EXACT | 0.90 |
| Thyroid Cancer | Malignant Thyroid Gland Neoplasm | CURATED_EXACT | 0.92 |
| Thyroid Carcinoma | Thyroid Gland Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| LAB TEST | Diagnostic Test | — | UNRESOLVED |
| Nuclear Medicine whole-body | Diagnostic Test | — | UNRESOLVED |
| Patient-led radiation monitor (SELFIE) | Device | — | UNRESOLVED |
| PET/CT imaging. | Diagnostic Test | — | UNRESOLVED |
| SPECT/CT imaging. | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Neuroendocrine Toumours
- description
- Patients will undergo 177LU-Dotatate Neoruendocrine Tumours MRT in accordance with existing protocols at GSTTFT. In addition, all MRT patients will be asked to undertake the following non-invasive procedures. * Post-treatment gamma camera (Planar Whole Body \& SPECT/CT) imaging to estimate disease/ target tissue and whole-body dose for Neuroendocrine and thyroid cancer MRT. * Post-treatment gamma camera planar Whole Body imaging for hyperthyroidism MRT. * Post-treatment patient-led self-monitoring. * Complete a feedback questionnaire relating to the use of self radiation monitoring.
- interventionNames
- Diagnostic Test: Nuclear Medicine whole-body
- Diagnostic Test: SPECT/CT imaging.
- Diagnostic Test: PET/CT imaging.
- Device: Patient-led radiation monitor (SELFIE)
- Diagnostic Test: LAB TEST
- label
- Thyroid Cancer
- description
- Patients will undergo 131I-Thyroid cancer MRT in accordance with existing protocols at GSTTFT. In addition, all MRT patients will be asked to undertake the following non-invasive procedures. * Post-treatment gamma camera (Planar Whole Body \& SPECT/CT) imaging to estimate disease/ target tissue and whole-body dose for Neuroendocrine and thyroid cancer MRT. * Post-treatment gamma camera planar Whole Body imaging for hyperthyroidism MRT. * Post-treatment patient-led self-monitoring. * Complete a feedback questionnaire relating to the use of self radiation monitoring.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients receiving MRT (177Lu-Peptide for Neuroendocrine Tumours and 131I for Thyroid Cancer and Benign Hyperthyroidism). * Women of childbearing potential must use a reliable method of contraception and have a documented negative pregnancy test immediately prior to MRT administration in accordance with routine clinical practice. * Able to comply with treatment plans, scheduled visits, all study whole body, SPECT/CT \& PET/CT imaging and follow-up. * Able to use a personalised dosimetry handheld device and record daily readings for 28 days post MRT. * Willing and able to give informed consent. Exclusion Criteria: * Pregnant or breastfeeding women. * Any other considerations that may make the patient unable to tolerate whole body, PET or SPECT scans. * Inability to use a personalised dosimetry handheld device and record the daily reading for 28 days post MRT. * Participants who are involved in current research or have recently been involved in any research prior to recruitment.
References
Publications (0)
Data not yet available